Hypoglycemia¶
Chapter 418 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Hypoglycemia is defined by Whipple’s triad: symptoms, low plasma glucose, and relief after glucose correction.
- Common causes include insulin/secretagogues, alcohol, critical illness, and endogenous hyperinsulinism (e.g., insulinoma).
- Neuroglycopenic symptoms (confusion, seizures) vs. adrenergic symptoms (tremor, sweating) guide clinical differentiation.
- Management prioritizes immediate glucose correction (oral or IV) and addressing underlying etiology.
- Prevention requires individualized glycemic targets, patient education, and avoidance of hypoglycemia triggers.
1. DEFINITION & OVERVIEW¶
Hypoglycemia is a clinical syndrome characterized by low plasma glucose (<50 mg/dL) with symptoms or signs of neuroglycopenia. It is a major complication of diabetes management, particularly with insulin or sulfonylureas. Severe hypoglycemia can cause neurological damage, cardiovascular events, and mortality.
Table 418-1: Causes of Hypoglycemia Across the Life Span¶
| Category | Causes |
|---|---|
| Ill or Medicated Individual | 1. Drugs (Insulin, sulfonylureas, alcohol) 2. Critical illness (Hepatic/renal/cardiac failure, sepsis) 3. Hormone deficiency (Cortisol, growth hormone) 4. Non–islet cell tumors |
| Seemingly Well Individual | 5. Endogenous hyperinsulinism (Insulinoma, nesidioblastosis) 6. Disorders of gluconeogenesis/fatty acid oxidation 7. Exercise 8. Accidental/surreptitious/malicious hypoglycemia 9. Prolonged fasting 10. Pregnancy |
1.1 Pathophysiology¶
Hypoglycemia disrupts glucose counterregulation mechanisms (insulin suppression, glucagon/epinephrine release). Defective glucose counterregulation leads to hypoglycemia unawareness and recurrent episodes. Endogenous hyperinsulinism (e.g., insulinoma, nesidioblastosis) or exogenous agents (insulin, sulfonylureas) are primary causes.
1.2 Clinical Impact¶
Hypoglycemia is a limiting factor in diabetes management. It increases cardiovascular risk, impairs quality of life, and contributes to mortality. Severe hypoglycemia is more common in T1DM than T2DM but increasingly prevalent in T2DM with insulin use.
2. EPIDEMIOLOGY¶
Hypoglycemia is common in diabetes, with ~6–10% of T1DM patients experiencing symptomatic episodes weekly. Severe hypoglycemia occurs in 1–3% of T1DM and 1–2% of T2DM patients annually. Risk factors include intensive insulin therapy, poor glycemic control, and comorbidities (e.g., renal failure, autonomic neuropathy).
2.1 Demographics¶
More prevalent in older adults, individuals with poor diabetes control, and those on insulin/sulfonylureas. T2DM patients with insulin use have higher prevalence due to increased insulin sensitivity and medication complexity.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Hypoglycemia arises from imbalances in glucose production/utilization. Key mechanisms include: - Exogenous agents (insulin, sulfonylureas) - Endogenous hyperinsulinism (insulinoma, nesidioblastosis) - Critical illness (hepatic/renal failure, sepsis) - Hormone deficiencies (cortisol, growth hormone) - Inborn errors of metabolism (GSD, fatty acid oxidation defects)
Table 41, 418-2: Physiologic Responses to Decreasing Plasma Glucose¶
| Response | Glycemic Threshold (mmol/L) | Physiologic Effects | Role in Hypoglycemia Prevention |
|---|---|---|---|
| fl Insulin | 4.4–4.7 | › R (fl R), increased lipolysis; › FFA | Primary glucose regulatory factor |
| › Glucagon | 3.6–3.9 | › R | Second defense against hypoglycemia |
| › Epinephrine | 3.6–3.9 | › R, fl R, increased lipolysis; › FFA and glycerol | Third defense against hypoglycemia |
| Symptoms | 2.8–3.1 | Recognition of hypoglycemia | Prompt behavioral defense |
3.1 Glucose Counterregulation¶
Normal glucose regulation involves insulin suppression, glucagon/epinephrine release, and hepatic gluconeogenesis. Defective counterregulation (e.g., HAAF) leads to hypoglycemia unawareness and recurrent episodes.
4. CLINICAL FEATURES¶
Symptoms vary by severity and duration: - Neuroglycopenic: Confusion, seizures, coma - Adrenergic: Tremor, sweating, palpitations - Autonomic: Hunger, paresthesias - Severe: Cardiac arrhythmias, death
4.1 Neuroglycopenic Manifestations¶
Central nervous system dysfunction due to glucose deprivation. Features include behavioral changes, confusion, fatigue, and seizures. Severe cases may progress to coma or death.
4.2 Adrenergic Symptoms¶
Autonomic activation from sympathetic discharge. Includes palpitations, tremor, anxiety, sweating, and hunger. These symptoms are often nonspecific and may precede neuroglycopenic signs.
5. DIFFERENTIAL DIAGNOSIS¶
Distinguish hypoglycemia from other conditions with similar symptoms: - Seizures (epilepsy, metabolic encephalopathy) - Psychiatric disorders (depression, schizophrenia) - Stroke/TIA - Electrolyte disturbances (hypokalemia, hyponatremia) - Drug toxicity (beta-blockers, alcohol withdrawal)
5.1 Non-Hypoglycemic Mimics¶
Conditions with confusion, seizures, or autonomic symptoms must be ruled out. Laboratory testing (e.g., glucose, electrolytes, imaging) and clinical context are critical for differentiation.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis requires Whipple’s triad: symptoms, low plasma glucose, and relief after glucose correction. Laboratory tests include: - Plasma glucose (confirm low levels) - Insulin/C-peptide/proinsulin (assess endogenous hyperinsulinism) - β -hydroxybutyrate (rule out ketotic hypoglycemia) - Glucagon stimulation test (for insulinoma) - Imaging (CT/MRI for tumors)
6.1 Diagnostic Algorithm¶
- Measure plasma glucose during symptoms (confirm hypoglycemia)
- Assess for Whipple’s triad
- Screen for exogenous agents (insulin, sulfonylureas)
- Evaluate for endogenous causes (insulinoma, GSD)
- Rule out critical illness/hormone deficiencies
7. MANAGEMENT & TREATMENT¶
Immediate treatment: Oral glucose (15–20 g) or IV dextrose (25 g). Long-term strategies include: - Adjusting medications (insulin/sulfonylurea doses) - Avoiding triggers (fasting, alcohol) - Glucagon/octreotide for acute episodes - Surgical resection for insulinoma - Diazoxide for nesidioblastosis
7.1 Acute Management¶
Oral glucose is first-line for conscious patients. IV dextrose (10–20 mL 50% glucose) for unconscious patients. Glucagon (1.0 mg IV) may be used in T1DM but is less effective in T2DM.
7.2 Chronic Management¶
Individualized glycemic targets, patient education, and avoidance of hypoglycemia triggers. Medical therapies (diazoxide, octreotide) for specific etiologies. Surgical intervention for tumors.
8. PROGNOSIS & COMPLICATIONS¶
Recurrent hypoglycemia increases cardiovascular risk and mortality. Severe hypoglycemia can cause permanent neurological damage, cardiac arrhythmias, and death. Long-term complications include hypoglycemia unawareness and autonomic failure.
8.1 Cardiovascular Risk¶
Severe hypoglycemia is associated with increased risk of myocardial infarction, stroke, and sudden cardiac death, particularly in T2DM patients. Risk persists for up to 1 year post-event.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Hypoglycemia is more common due to increased insulin sensitivity. Monitor closely and adjust insulin doses. Pediatrics: Recurrent hypoglycemia may indicate GSD or inborn errors. Elderly: Higher risk of severe hypoglycemia due to autonomic neuropathy and comorbidities.
9.1 Insulinoma in Pregnancy¶
Insulinomas may present with hypoglycemia during pregnancy. Management includes surgical resection if symptomatic, with careful monitoring of maternal and fetal outcomes.
10. KEY POINTS & CLINICAL PEARLS¶
- Whipple’s triad is essential for diagnosis.
- Insulin/sulfonylureas are the most common causes.
- Neuroglycopenic vs. adrenergic symptoms guide differentiation.
- Immediate glucose correction is critical for severe cases.
- Prevent recurrence with patient education and individualized glycemic targets.